News

Study to explore effects of CBD in dogs with osteoarthritis

Around one in five dogs are diagnosed with osteoarthritis in their lifetime.

Sarah Sinclair
dogs CBD

A new study to explore how CBD can relieve pain and improve mobility in dogs is underway in the US.

Researchers at the Colorado State University (CSU) veterinary program are investigating the effects of cannabinoids in dogs suffering from osteoarthritis. 

The study, which is being held in partnership with popular US CBD company, CbdMD Therapeutics, will explore the effects of its proprietary cannabinoid blend on dogs with the condition.

Around one in five dogs are diagnosed with osteoarthritis in their lifetime. 

Increasing numbers of pet owners are turning to CBD products in an attempt to help relieve their animal’s pain and improve mobility, which in turn can dramatically improve quality of life, particularly in older pets. 

An Australian medical cannabis company recently reported promising results in a pilot study of a cannabinoid-based veterinary medicine for pain and inflammation in dogs. 

Others find that its anxiety-relieving effects help keep animals calm in stressful situations, such as around fireworks. 

CbdMD’s Paw CBD brand is one of the leading CBD animal health brands in the U.S. 

The results from this study, expected to be complete in spring 2022, are expected to provide validating data on the efficacy of the company’s products in reducing pain and improving joint mobility in dogs. 

Martin Sumichrast, chairman and co-CEO of CbdMD, said: “With almost one billion dogs globally and over 75 million in the US, osteoarthritis affects millions of our loved ones.

“Paw CBD is committed to providing products that can improve our pet’s quality of life and provide relief for joint discomfort for the millions of pets who suffer from this disease.”

He added: “Our partnership with CSU will serve as the foundation for future work where we will explore the clinical impact of our proprietary broad spectrum cannabinoid blend on pain and mobility in our pets.”

Sarah Sinclair

Sarah Sinclair

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.